Stock Ratings / Health Care / QNTM / options

ACTU (35) TXMD (34) BYSI (34) KPTI (31) ⌘ Pro Terminal →

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) Options Positioning, Max Pain & Unusual Sweeps

$2.44 +2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.45

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $20.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QNTM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.44 (+2.95% 1D, market cap $20.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, QNTM ranks #385 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QNTM compare to ACTU and TXMD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $20.4M) and TXMD (TherapeuticsMD Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $21.2M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QNTM?

▼

For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #385 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.45 (+0.34%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNTM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY QNTM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($578.5K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$2.82-14.5% Next Q

Q2 (-2Q)

Grade C-$2.41-8.3% Next Q

Q3 (-1Q)

Grade D$2.21+10.4% Next Q

Current

Grade D$2.44-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QNTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QNTM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.10) and Max Pain ($2.56) forces dealer call-delta covering toward $13.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QNTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “QNTM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (QNTM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for QNTM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNTM)

✓Walkthrough of QNTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QNTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.08%🛡️ HOLDING TREND SUPPORT

2026-11-02O $2.37H $2.44L $2.37C $2.44VOL 52.7K

RES: $4.31SUP: $1.98SMA50: $3.10SMA200: $3.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QNTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QNTM Butterfly Map → + Track QNTM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QNTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QNTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QNTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNTM)

Health Care Rank #385 of 1016 ⚔️ ACTU vs QNTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QNTM vs. ACTU, TXMD, BYSI, KPTI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) ranks #385 by composite RQD confidence (46/100, grade D) and #831 by equity capitalization ($20.7M). Within this direct 5-issuer industry benchmark cohort, QNTM leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QNTM ACTIVE Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D	46/100	—	—	—	+2.95%	$20.7M	Benchmark Subject
ACTU Actuate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-3.21%	$20.4M	/actu-vs-qntm →
TXMD TherapeuticsMD Inc.	E	34/100	—	—	-12.9%	+2.24%	$21.2M	/txmd-vs-qntm →
BYSI BeyondSpring Inc.	E	34/100	—	—	-35.0%	-1.49%	$21.2M	/bysi-vs-qntm →
KPTI Karyopharm Therapeutics Inc.	E	31/100	—	—	-35.0%	+5.73%	$20.0M	/kpti-vs-qntm →

2. QNTM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $20.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. QNTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does QNTM compare to ACTU and TXMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for QNTM?

Where is QNTM trading relative to its 50-day, 200-day, and 52-week technical levels?

QNTM last traded at $2.44 (+2.95% on volume of 52,685 shares), positioning the stock -21.29% below its 50-day simple moving average ($3.10) and -36.79% below its 200-day simple moving average ($3.86). Across its 52-week range of $2.07 to $12.46, QNTM sits at the 3.6% percentile with a 14-day RSI of 38.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.14 to $2.74).

QNTM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is QNTM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for QNTM.

Direct Sub-Reports: QNTM RQD Cockpit QNTM 12M Forecast QNTM Earnings & Move QNTM Dividends & DRIP QNTM Insiders & 13F QNTM Whale Options QNTM Profit Sankey QNTM News & Why